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A B S T R A C T
Purpose
For over 30 years, the place of consolidation high-dose chemotherapy in Ewing sarcoma (ES)
has been controversial. A randomized study was conducted to determine whether consolida-
tion high-dose chemotherapy improved survival in patients with localized ES at high risk for relapse.
Methods
Randomization between busulfan and melphalan (BuMel) or standard chemotherapy (vincristine,
dactinomycin, and ifosfamide [VAI], seven courses) was offered to patients if they were younger
than 50 years of age with poor histologic response ($ 10% viable cells) after receiving vincristine,
ifosfamide, doxorubicin, and etoposide (six courses); or had a tumor volume at diagnosis$ 200mL if
unresected, or initially resected, or resected after radiotherapy. A 15% improvement in 3-year event-
free survival (EFS) was sought (hazard ratio [HR], 0.60).
Results
Between 2000 and 2015, 240 patients classiﬁed as high risk (median age, 17.1 years) were randomly
assigned to VAI (n = 118) or BuMel (n = 122). Seventy-eight percent entered the trial because of poor
histologic response after chemotherapy alone. Median follow-up was 7.8 years. In an intent-to-treat
analysis, the risk of event was signiﬁcantly decreased by BuMel comparedwith VAI: HR, 0.64 (95%CI,
0.43 to 0.95; P = .026); 3- and 8-year EFS were, respectively, 69.0% (95%CI, 60.2% to 76.6%) versus
56.7% (95%CI, 47.6% to 65.4%) and 60.7% (95%CI, 51.1% to 69.6%) versus 47.1% (95%CI, 37.7%
to 56.8%). Overall survival (OS) also favored BuMel: HR, 0.63 (95% CI, 0.41 to 0.95; P = .028); 3- and
8-year OS were, respectively, 78.0% (95% CI, 69.6% to 84.5%) versus 72.2% (95% CI, 63.3% to
79.6%) and 64.5% (95%CI, 54.4% to 73.5%) versus 55.6% (95%CI, 45.8% to 65.1%). Results were
consistent in the sensitivity analysis. Two patients died as a result of BuMel-related toxicity, one after
standard chemotherapy. Signiﬁcantly more BuMel patients experienced severe acute toxicities from
this course of chemotherapy compared with multiple VAI courses.
Conclusion
BuMel improved EFS and OS when given after vincristine, ifosfamide, doxorubicin, and etoposide
induction in localized ES with predeﬁned high-risk factors. For this group of patients, BuMel may be
an important addition to the standard of care.
J Clin Oncol 36:3110-3119. © 2018 by American Society of Clinical Oncology
INTRODUCTION
Treatment advances in Ewing sarcoma (ES) have
largely resulted from amultidisciplinary approach
to clinical trials conducted by national and in-
ternational cooperative groups. Over the years,
these trials have answered key chemotherapy
questions and better deﬁned risk groups, allowing
tailored treatment strategies. Prolonged disease-free
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survival is achieved in the majority of patients with localized ES after
treatment with multiagent chemotherapy and primary tumor con-
trol.1-4 Larger initial tumor volume is a well-deﬁned adverse prog-
nostic factor,5-8 the predictive power of which is over-ridden by the
extent of histologically determined chemotherapy-induced necrosis
assessed in resected primary tumors.4,8-11 These observations can be
used to deﬁne subgroups of patients with localized ES in whom
treatment interventions to improve survival may be examined.
The rationale for high-dose therapy (HDT) in ES was de-
veloped to exploit an alkylating agent dose-response relationship.
Several single-arm studies have indicated high-dose chemo-
therapy efﬁcacy using historical controls in newly diagnosed
metastatic or recurrent ES, using various drugs or combinations
with or without total-body irradiation.12-18 Two national non-
randomized studies evaluated the role of busulfan-melphalan
(BuMel) in patients with poor histologic response and suggested its
potential beneﬁt compared with historical controls treated with
conventional chemotherapy.19,20 Because these encouraging results
were based on uncontrolled comparisons, a randomized comparison
of high-dose chemotherapy against standard chemotherapy was
therefore incorporated in two multinational controlled trials, Euro-
E.W.I.N.G.99 and EWING-2008. In the selected high-risk pop-
ulation, termed R2Loc, the primary objective was to evaluate
whether HDT using BuMel improved event-free survival (EFS)
compared with standard chemotherapy (vincristine, dactinomycin,
ifosfamide [VAI]).
METHODS
Study Design
The R2Loc trial was an international, randomized, superiority trial
comparing consolidation treatment with BuMel or seven VAI courses in
a two-parallel-group design. The R2Loc randomized trial was a com-
ponent of the Euro-E.W.I.N.G.99 study (ClinicalTrials.gov identiﬁer:
NCT00020566) recruiting all patients with ES at diagnosis, enrolled by
four cooperative groups: European Organization for Research and
Treatment of Cancer (EORTC), Gesellschaft fu¨r Pa¨diatrische Onkologie
und Ha¨matologie (GPOH), French Society of Pediatric Oncology and
French Sarcoma Group, and the UK Children’s Cancer and Leukaemia
Group.1,21,22 From May 2010, patients from GPOH were recruited in the
same R2Loc randomized trial conducted through the EWING-2008
study (ClinicalTrials.gov identiﬁer: NCT00987636).
Patients
Eligibility requirements were age younger than 50 years; enrollment at
diagnosis either in Euro-E.W.I.N.G.99 or EWING-2008 studies for newly
diagnosed biopsy-proven ES; localized disease classiﬁed as high risk because
of poor histologic response to induction chemotherapy (residual viable
cells$ 10%) for patients undergoing surgery after induction chemotherapy
alone or because of large tumor volume at diagnosis ($ 200 mL) in
unresected or initially resected tumors or resected tumors with preoperative
irradiation, but patients with a small unresected tumor were also eligible in
case of poor clinical response to induction chemotherapy (, 50% radiologic
reduction in soft tissue disease component); and no medical contraindi-
cation to treatment. After amendment, because of busulfan-related radio-
sensitivity,23 patients expected to receive radiotherapy. 30 Gy to the spinal
cord (Amendment July 2004) or . 45 Gy to large intestinal volume
(Amendment November 2008) were no longer eligible. Written informed
consent was obtained from all patients and/or their parents/guardians before
enrollment.
Treatments
Induction chemotherapy consisted of six chemotherapy courses
combining vincristine, ifosfamide, doxorubicin, and etoposide (VIDE).21,24
After one VAI course, allocated consolidation treatment was either seven VAI
courses (VAI arm) or one course of high-dose BuMel chemotherapy with
autologous stem-cell transplant (BuMel arm). Treatment schedule and
chemotherapy details are in the Data Supplement.
Local therapy was tailored to patient and tumor characteristics, and
included surgery with complete surgical removal wherever feasible, ra-
diotherapy, or a combination of both (Data Supplement). Stem-cell
harvest was undertaken according to local practice after VIDE course 2.
Randomization
Random assignment was performed after six VIDE courses plus one
VAI consolidation course, after surgery and assessment of histologic re-
sponse when applicable. Randomization was balanced and stratiﬁed
according to cooperative group, sex, age (younger than 25 years), and
local treatment (resection after chemotherapy alone with or without
postoperative radiotherapy v initial surgery v resection after chemo-
therapy and radiotherapy v radiotherapy only). Centralized randomi-
zation software was used in all data centers, ensuring the concealment of
the next patient allocation. The GPOH data center used permuted blocks
of four. In the other data centers, randomization was also balanced by the
treating center using dynamic allocation of treatment (minimization
with a random factor set at 0.8).
End Points and Assessments
The primary end point was EFS, deﬁned as the time from ran-
domization to the date of the ﬁrst failure assessed by the investigator
(progression, relapse, second malignancy, or death, whatever the cause).
Follow-up was planned every 3 months during the ﬁrst 3 years, every
6 months during years 4 and 5, then yearly, regardless of treatment
compliance. Overall survival (OS) since randomization was a secondary
efﬁcacy end point, considering all deaths, whatever the cause.
Central imaging review of tumor volume and response, and path-
ologic review were not undertaken. Compliance with treatment and
toxicity were monitored. All chemotherapy doses were recorded, as well as
the reasons for dose reduction or delay. Acute toxicity related to che-
motherapy was assessed after each course, using a list of 22 selected items
from the National Cancer Institute Common Toxicity Criteria version 2.0
and Bearman’s criteria for sinusoidal obstruction syndrome.25 Other
adverse reactions were speciﬁed. A modiﬁed list was used to evaluate
toxicity after radiotherapy, using Radiation Therapy Oncology Group
classiﬁcation for 17 toxicities.26 For each toxicity type, the maximum grade
observed over the whole maintenance treatment was computed, including
radiotherapy to the primary site. Grade 4 hematologic toxicities and grade
3 or higher of all nonhematologic toxicities were considered severe.
Statistical Analysis
The study was designed to ensure 80% power for a 40% reduction in
the risk of an event in the BuMel arm compared with the VAI arm (expected
3-year EFS, 70% v 55%; hazard ratio [HR], 0.60) with a two-sided log-rank
test a of .05. The initial target sample size was 328 patients (124 events).27
With support from the independent data monitoring committee, re-
cruitment was stopped before reaching this target because of low accrual.
This is the ﬁnal analysis, on the basis of data as of July 2016.
Preplanned efﬁcacy stopping rules were deﬁned using the a spending
function approach with O’Brien-Fleming boundaries.28,29 These analyses
were only disclosed to the independent monitoring committee. Survival
rates (EFS and OS) were estimated using the Kaplan-Meier method with
Rothman’s 95% CIs. Median follow-up was estimated using the reverse
Kaplan-Meier method. The HR of event (EFS) and the HR of death (OS)
were estimated in Cox models. The point estimate of the HR of event, its
CI, and the P value were corrected for the four previous interim analyses
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using the inverse normal method.31 The primary efﬁcacy analysis was
performed according to the patients’ randomly assigned treatments (ie, by
intention-to-treat population). Post hoc sensitivity analyses were performed,
(1) adjusting for age (in four categories:, 12, 12 to 18, 18 to 25,. 25 years)
and (2) excluding patients with a major treatment modiﬁcation (as-treated;
Data Supplement). The heterogeneity of treatment effect (BuMel v VAI)
on EFS according to stratiﬁcation variables and tumor volume, tumor site,
and histologic response (post hoc exploratory analysis) were evaluated in
multivariable models, including interaction terms, and illustrated in a forest
plot. Because the EFS is a composite end point, a competing risk approach
was also used to estimate the effect of treatment on the risk of metastases
using subdistribution HRs considered competing events: local progression/
relapse without concomitant metastases, secondary malignancy, and death
without prior metastases (post hoc analysis).32,33
Safety analyses were performed on the safety set, excluding patients
who did not receive the assigned treatment (as-treated population). For
Assigned to Bu-Mel (n = 122)
Eligible for R2loc trial (n = 114)
(n = 8)Not eligible for R2loc trial
Patients potentially eligible not included (n = 365)
(n = 144)
(n = 77)
(n = 123)
(n = 21)
Patient/parent refusal
Physician refusal
Miscellaneous reason
Unknown reason yet
Patients with localized high-risk disease
enrolled in the Euro-E.W.I.N.G.99-EWING-2008 studies
(N = 753) 
Patients enrolled in R2Loc randomized trial
(n = 240)
Patients potentially eligible
(n = 605)
Lost-to-follow-up in the first 3 years
(n = 1)
Lost-to-follow-up in the first 3 years
(n = 1)
Received assigned intervention (n = 116)
(n = 1)Received Bu-Mel
(n = 1)With missing information
In the intention-to-treat analysis    (n = 118)
In the as-treated data set      (n = 116)
High-risk patients screened for eligibility
(n = 716)
Patients not meeting eligibility criteria
(n = 111)
Progressions or deaths
     before randomization timepoint
(n = 37)
Assigned to VAI (n = 118)
Eligible for R2loc trial (n = 114)
(n = 4)Not eligible for R2loc trial
Received assigned intervention (n = 93)
(n = 21)
(n = 6)
(n = 2)
Did not receive Bu-Mel HDT
Received another HDT
With missing information
In the intention-to-treat analysis
In the as-treated data set    (n = 93)
(n = 122)
Fig 1. Trial proﬁle. A total of 111 patients
with disease classiﬁed as localized high-risk
disease assessed for eligibility did not meet
eligibility criteria: insufﬁcient diagnosis criteria
or diagnosis rejected (n = 14); persisting tox-
icity related to previous treatment and/or
contraindication to planned treatment (n = 78),
including contraindication to busulfan and
melphalan (BuMel) because of planned ra-
diotherapy to an axial site (n = 36); early ra-
diotherapy (n = 13); psychological problems
(n = 6); 123 patients meeting eligibility criteria
were not enrolled because of other reasons.
HDT, high dose therapy; R2Loc, selected high-
risk population; VAI, vincristine, dactinomycin,
and ifosfamide.
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each toxicity category, the relative risk of having experienced a severe
toxicity in BuMel versus VAI was estimated.
Estimates are provided with 95% CIs. All tests are two sided. The
analyses were performed using SAS 9.3 software (SAS Institute, Cary, NC).
Study Oversight
Study protocols were approved by an independent ethics committee
and the appropriate institutional review boards. The studies were con-
ducted in accordance with the ethical principles of the Declaration of
Helsinki and with Good Clinical Practice guidelines. The trial was designed
jointly by the senior academic authors from the participating cooperative
groups. The protocols are available online. Data were analyzed by the
biostatisticians at Institut Gustave Roussy and reviewed by the statisticians’
board. The ﬁrst draft of this article was written by M.C.L.D., O.O., and J.W.
All authors contributed to subsequent drafts and made the decision to
submit the manuscript for publication. None of the funders had a role in
study design, collection, analysis, or interpretation of data.
RESULTS
Patients
Between February 2000 and December 2015, 716 patients
with a localized tumor fulﬁlling the predeﬁned high-risk criteria,
enrolled in 131 centers from 13 countries, were assessed for
eligibility. Among them, 111 did not meet eligibility criteria
(details in the legend of Fig 1). Of 605 eligible patients, 221 were
not enrolled because of patient/parent (n = 144) or physician (n =
77) refusal, 123 for other reasons, and 21 for whom the reason
was unknown; 240 patients were included in the randomized
trial: 118 assigned to VAI and 122 assigned to BuMel (Fig 1). The
median age was 17.1 years (range, 11 months to 44.7 years). The
baseline characteristics were well balanced between the two
groups (Table 1), although over the course of the study, some
changes were notable, with a greater proportion with less fa-
vorable histologic response represented (Data Supplement).
Overall, 188 of the 240 patients (78%) entered the trial because of
poor histologic response after chemotherapy alone. Median follow-
up was 7.8 years and was not signiﬁcantly different between treat-
ment groups (Data Supplement). Among the 240 enrolled patients,
four patients in the VAI arm and eight patients in the BuMel arm
were not eligible (Data Supplement).
One patient allocated to VAI received BuMel on his request. In
the BuMel arm, 21 patients did not receive any HDT because of
patient refusal (n = 11), medical reason (n = 7), physician decision
(n = 2), or failure to collect peripheral stem cells (n = 1); six patients
received HDTother than BuMel because of physician decision in ﬁve
Table 1. Patient and Tumor Baseline Characteristics
Characteristics VAI (n = 118) BuMel (n = 122) Total (n = 240)
Gender, No. (%)
Male 73 (62) 75 (61) 148 (61)
Female 45 (38) 47 (39) 92 (38)
Median age, years (range) 17.1 (0.9-43) 17.4 (2.5-45) 17.1 (0.9-45)
Recruiting group , No. (%)
EORTC 8 (7) 9 (7) 17 (7)
UKCCLG 20 (17) 21 (17) 41 (17)
SFCE/GSF/Unicancer 37 (31) 37 (30.5) 74 (31)
GPOH 42 (36) 42 (34.5) 84 (35)
GPOH-Ewing2008 11 (9) 13 (11) 24 (10)
Follow-up
Median duration, years (range) 8.7 (0.1-13.4) 7.4 (0.08-13.9) 7.8 (0.08-13.9)
Lost to follow-up in the ﬁrst 3 years, No. (%) 1 (1) 1 (1) 2 (2)
Primary tumor site, No. (%)
Axis 66 (56) 70 (57) 136 (57)
Limb 52 (44) 52(43) 104 (43)
Tumor volume (1 MD), No. (%)
, 200 mL 57 (48) 59 (48) 116 (48)
$ 200 mL 60 (52) 63 (52) 123 (52)
Classiﬁcation high-risk group/local treatment, No. (%) 118 122 240
Poor histologic response after chemotherapy alone 93 (79) 95 (78) 188 (78)
10%-29% viable cells 39 (33) 42 (34) 81 (34)
$ 30% viable cells 52 (44) 51 (42) 103 (43)
Poor histologic response, NOS 2 (2) 2 (2) 4 (2)
Large tumor, histologic response not applicable 21 (18) 19 (16) 40 (17)
Preoperative radiotherapy 1 (1) 2 (2) 3 (1)
Initial surgery 6 (5) 6 (5) 12 (5)
Exclusive radiotherapy 14 (12) 10 (8) 24 (10)
Other 0 1 (1) 1 (, 1)
Other 0 (0) 2 (2) 2 (1)
Small tumor with exclusive radiotherapy, but poor clinical
response
0 (0) 2 (2) 2 (1)
Nonhigh-risk group* 4 (3) 6 (5) 10 (4)
Abbreviations: BuMel, busulfan and melphalan; EORTC, European Organization for Research and Treatment of Cancer; GPOH, Gesellschaft fu¨r Pa¨diatrische Onkologie
und Ha¨matologie; GSF, French Sarcoma Group; MD, missing data; NOS, not otherwise speciﬁed; SFCE, French Society of Pediatric Oncology; UKCCLG, Children’s
Cancer and Leukaemia Group; VAI, vincristine, dactinomycin, and ifosfamide.
*As detailed in the Data Supplement, 10 patients were enrolled in the randomized trial, although they were ineligible.
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No. Events / No. Patients
BuMel Better VAI Better
Poor response
Age, years
Category
< 12 
12-18 
18-25
> 25
Recruiting group
EORTC
UKCCLG
French group
GPOH
Tumor site
Limb
Axis
Tumor volume
< 200 ml
≥ 200 ml
High-risk group
Large tumor
Poor response, %
10-29 cells
≥ 30 cells
Overall
VAI
9/24
21/40
14/25
16/29
5/8
10/20
23/37
22/53
27/52
33/66
22/57
37/60
49/93
10/21
24/39
24/52
60/118
BuMel
8/33
11/36
10/25
16/28
4/9
8/21
16/37
17/55
16/52
29/70
19/59
26/63
37/95
7/19
14/42
23/51
45/122
0.2 5.01.0
Hazard Ratio
0.64 (0.25 to 1.67)
0.53 (0.25 to 1.10)
0.52 (0.23 to 1.17)
1.04 (0.52 to 2.08)
0.56 (0.15 to 2.09)
0.69 (0.27 to 1.76)
0.61 (0.32 to 1.16)
0.67 (0.35 to 1.26)
0.49 (0.26 to 0.91)
0.79 (0.48 to 1.31)
0.77 (0.42 to 1.43)
0.55 (0.33 to 0.92)
0.65 (0.42 to 1.00)
0.74 (0.28 to 1.96)
0.42 (0.22 to 0.82)
0.97 (0.55 to 1.73)
0.64 (0.43 to 0.94)
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.99
.23
.41
.51
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Fig 2. (A and B) Event-free survival (EFS) and (C) overall survival. (A) Kaplan-Meier estimates of EFS by treatment group, on the intention-to-treat (ITT) population.
At the time of this analysis (cutoff date, Jan 1, 2016), 105 events were reported: 60 in the vincristine, dactinomycin, and ifosfamide (VAI) group and 45 in the busulfan
and melphalan (BuMel) group. (B) Forest plot of EFS according to subgroups. The hazard ratio of events by subgroup were estimated in a Cox proportional hazards
model, on the ITT population including all patients, except for the (1) assessment of treatment effect according to tumor volume: we excluded one patient with
missing data; (2) assessment of treatment effect by the high-risk group deﬁnition (poor response v large tumor): we excluded 10 patients who were not classiﬁed as
high risk (listed in the Data Supplement) and two patients who entered the trial for a small tumor with exclusive radiotherapy, but poor (continued on next page)
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patients and BuMel contraindication in one patient (Data Supple-
ment). These 28 patients were excluded in the as-treated analysis.
When grouped by selected factors, the proportions of patients
randomly assigned to those not randomly assigned varied (data not
shown). There were differences by study year, study group, age,
tumor volume, histologic response, and treatment with radiotherapy.
Efficacy
A total of 105 events were reported (VAI arm, 60; BuMel arm,
45): 13 local progressions or local relapses, 80 distant metastases
(including lung metastases in 51 patients), ﬁve secondary malig-
nancies, and seven deaths as ﬁrst events (Data Supplement), in-
cluding three treatment-related deaths.
EFS for all 240 randomly assigned patients was 62.9% (95%
CI, 56.6% to 68.9%) at 3 years and 54.0% (95% CI, 47.2% to
60.7%) at 8 years. The treatment effect of BuMel was estimated as
an HR of 0.64 (95% CI, 0.43 to 0.95; P = .026), corrected for the
four previous interim analyses. Three-year EFS rates for VAI and
BuMel were 56.7% (95% CI, 47.6% to 65.4%) and 69.0% (95% CI,
60.2% to 76.6%), respectively, with this improvement being
sustained at 8 years: 47.1% (95% CI, 37.7% to 56.8%) versus
60.7% (95%CI, 51.1% to 69.6%; Fig 2A; Table 2), respectively. The
treatment effect estimate seems greater in the sensitivity analysis,
when patients with protocol violations were excluded (Table 2). As
illustrated in Figure 2B, no signiﬁcant heterogeneity of the
treatment effect was observed according to cooperative group,
tumor site, tumor volume, or eligibility criteria for high-risk
classiﬁcation. However, patients with an intermediate poor re-
sponse may beneﬁt more than those with a very poor response
(10% to 29% v$ 30% viable cells; interaction test, P = .06), as well
as older patients (# 25 v. 25 years of age; P = .12). Improvement
in EFS was mostly related to a reduction in the risk of metastases
(subdistribution-HR, 0.58; 95% CI, 0.37 to 0.90; P = .02; Data
Supplement).
Beneﬁt from BuMel was also observed in OS. Ninety deaths
were reported (VAI, 53; BuMel, 37), leading to an HR of 0.63 (95%
CI, 0.41 to 0.95; P = .028). Three-year OS was 72.2% (95% CI,
63.3% to 79.6%) and 78.0% (95%CI, 69.6% to 84.5%) for VAI and
BuMel, respectively (Fig 2C), and 75.1% (95%CI, 69.2% to 80.2%)
overall. Eight-year OS was 55.6% (95% CI, 45.8% to 65.1%) versus
64.5% (95% CI, 54.4% to 73.5%).
Safety
Signiﬁcantly more BuMel patients experienced severe acute
toxicities (Fig 3), but toxicity arose from a single high-dose course
versus multiple VAI courses (Data Supplement). The effect of
BuMel on the risk of severe acute toxicity did not differ between
patients older than 25 years and younger patients (Data Supple-
ment). Three treatment-related deaths were reported in the BuMel
arm, although one was in a patient who did not receive BuMel
because of renal dysfunction. One patient with a cervical spine
primary site died as a result of myelopathy related to radiotherapy
administered after BuMel, and one patient with a chest wall
primary site died as a result of acute respiratory distress syndrome
associated with pancytopenia 5 months after receiving BuMel.
DISCUSSION
In the subgroup of patients with localized ES speciﬁcally deﬁned
for this study, treatment with BuMel conferred a signiﬁcant,
sustained, and clinically meaningful improvement (European
Society for Medical Oncology–Magnitude of Clinical Beneﬁt Scale
grade A) in EFS and OS.34 This outcome was despite the ﬁnal
analysis being conducted after recruitment of only 240 of a planned
328 patients and was sustained with prolonged follow-up. This
ﬁnding is particularly signiﬁcant, given the observation that cure
rates in this important cancer of children and young people have
improved modestly at best over recent decades and that the
expanding knowledge of the biology of ES has, to date, not resulted
in the introduction of new agents into standard care.35
Several factors deserve more detailed consideration. First, this
was a complex but pragmatic trial performed by an experienced
multinational cooperative group that encompassed a large pro-
portion of major pediatric and sarcoma-treating centers in Europe.
Despite this, recruitment fell short of the recruitment rates pro-
posed at study initiation. The study was closed before the planned
event/patient target was reached because of some investigators’
concerns that rates of participation in the study were too low to be
sustainable. Of patients within the study registration cohort, one
third of those fulﬁlling the deﬁnition of localized high-risk disease
were ultimately randomly assigned, with evidence of low ac-
ceptability of the study question to both clinicians and patients. We
acknowledge that this limits the external validity of our ﬁndings.
However the description of a screened population and the estimate
of randomization rate are missing from other studies, and sets this
intervention into a clinically meaningful context.
The use of histologic response as the main selection criterion
identiﬁes a population of patients with some degree of initial drug
resistance. In R2Loc, this is supplemented by other high-risk pa-
tients, accounting for 20% of randomly assigned patients, for whom
histologic response was not available, those with tumors . 200 mL
who had undergone primary surgery or had early radiotherapy or
exclusive radiotherapy. This subset of patients may include patients
with unidentiﬁable good response to induction chemotherapy.
Overall, the BuMel effect seemed consistent across main strata
(cooperative group, tumor site, tumor volume, or eligibility criteria
for high-risk classiﬁcation). Within the poor histologic response
spectrum, it is possible that BuMel may have less beneﬁt in those
with poor response, although, given that this was an observation
from a post hoc exploratory analysis, it is insufﬁcient evidence to be
clinical response (too small category); and (3) assessment of treatment effect according to the grading of histologic response in patients with poor response:
we focused the analysis on the 188 patients who entered the trial because of a poor histologic response and excluded four patients with poor response not otherwise
speciﬁed. French group: French Society of Pediatric Oncology/French SarcomaGroup/Unicancer. Concerning the interaction between treatment effect and age, the P value
was .12 when agewas considered in two categories using the cutoff of 25 years as deﬁned at the design stage to stratify the randomization. (C) Kaplan-Meier estimates for
overall survival by treatment group on the ITT population. EORTC, European Organization for Research and Treatment of Cancer; GPOH, Gesellschaft fu¨r Pa¨diatrische
Onkologie und Ha¨matologie; UKCCLG, UK Children’s Cancer and Leukaemia Group
(Continued).
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used alone to exclude patients from treatment with BuMel if all other
criteria for possible beneﬁt are fulﬁlled. It is also possible that there
may be less beneﬁt for older patients, although this observation may
be by chance, and the test for interaction was not signiﬁcant.
BuMel was chosen as HDT based on international transplant
registry data16,18 and previous work by the French Society of Pe-
diatric Oncology.20 Concerns about interaction with radiotherapy,
including fatal toxicity, led to a protocol amendment after which
patients requiring large-volume or high-dose radiotherapy to critical
organs were excluded from randomization.23 There is little evidence
to deﬁne thresholds for concurrent use of radiotherapy and bu-
sulfan. Others have reported its use after whole-lung irradiation
without signiﬁcant toxicity.36 There are no data to support equiv-
alent efﬁcacy with treosulfan, which, although closely related to
busulfan, is less radiosensitizing.
We chose to compare BuMel against seven cycles of main-
tenance chemotherapy only. Given that the effect of HDT in this
series is seen in a reduction in the incidence of subsequent me-
tastases, which were often pulmonary, we cannot exclude that
whole-lung irradiation would have similar beneﬁts.37,38
Extrapolation of beneﬁt to other settings in ES is to be
cautioned against. A similar effect of BuMel on survival in pa-
tients presenting with pulmonary metastases was not observed
when bilateral pulmonary irradiation was added to conventional
Table 2. EFS and Overall Survival Analysis, Main Analysis on the Intention-To-Treat Population, and Sensitivity Analysis on the As-Treated Population
Outcome
Intention-To-Treat Analysis As-Treated Population*
VAI Arm (n = 118)
BuMel Arm
(n = 122) VAI Arm, n = 116 BuMel Arm (n = 93)
EFS
No. and type of events 60 45 60 33
Progression/relapse 56 37 56 27
Local progression or relapse 8 5 8 4
Without metastases 48 32 48 23
Distant metastases
With or without local
progression or relapse
Secondary malignancy 3 2 3 2
Death as ﬁrst reported event† 1 6 1 4
Treatment-related death 0 3‡ 0 2
Death from other cause 1 2§ 1 1
Death from unknown cause 0 1 0 1
3-year EFS since
randomization, % (95% CI)
56.7 (47.6 to 65.4) 69.0 (60.2 to 76.6) 56.0 (46.8 to 64.8) 71.7 (61.8 to 79.9)
8-year EFS since
randomization, % (95% CI)
47.1 (37.7 to 56.8) 60.7 (51.1 to 69.6) 46.3 (36.8 to 56.0) 62.8 (51.9 to 72.6)
HR of event (95% CI)k 1 0.64 (0.43 to 0.95)¶ 1 0.57 (0.37 to 0.88)
P .026# .010
Adjusted HR of event (95% CI)# 1 0.65 (0.44 to 0.96) 1 0.58 (0.38 to 0.89)
P .032 .012
Overall survival
No. and cause of deaths 53 37 53 28
Due to progression/relapse 48 31 48 24
Treatment-related death 0 3§ 0 2
Secondary malignancy 4 0 4 0
Other cause 1 2k 1 1
Unknown cause 1 1
3-y OS from randomization, %
(95% CI)
72.2 (63.3 to 79.6) 78.0 (69.6 to 84.5) 71.7 (62.8 to 79.2) 79.2 (69.8 to 86.3)
8-y OS from randomization, %
(95% CI)
55.6 (45.8 to 65.1) 64.5 (54.4 to 73.5) 55.0 (45.1 to 64.5) 65.4 (54.1 to 75.3%)
HR of death (95% CI)k 1 0.63 (0.41 to 0.95) 1 0.58 (0.37 to 0.92)
P .028 .019
Adjusted HR of death
(95% CI)#
1 0.64 (0.42 to 0.97) 1 0.59 (0.37 to 0.93)
P .035 .022
Abbreviations: BuMel, busulfan and melphalan; EFS, event-free survival; HR, hazard ratio; OS, overall survival; VAI, vincristine, dactinomycin, and ifosfamide.
*As-treated data set: excluding 31 patients (two in the VAI arm, 29 in the BuMel arm); 28 patients with amajor treatment modiﬁcation (Data Supplement); three patients
with missing information about received treatment.
†The seven deaths as ﬁrst events are detailed in the Data Supplement.
‡Three treatment-related deaths were reported in the BuMel arm, but one occurred in a patient who did not receive BuMel (allocated to BuMel, but received two VAI
courses and no BuMel because of limited renal function; renal insufﬁciency and cardiac insufﬁciency, leading to death 3 months after randomization).
§Two deaths due to another cause were reported in the BuMel arm, but one occurred in a patient who did not receive BuMel because of patient choice.
║Hazard ratios with their 95% CIs and P values were estimated in Cox models including only the treatment effect as a covariable, with prior check of the proportional
hazards assumption by adding a time-interaction term and by using the Martingale-based residuals.30
¶The HR provided in the table for themain analysis of EFSwas corrected for the four previous interim analyses using the inverse normal method. Before this correction,
the HR was 0.64 (95% CI, 0.43 to 0.94; P = .023).
#Hazard ratios with their 95%CIs and P values were estimated in Coxmodels including the treatment effect and age in four categories (, 12, 12 to 18, 18 to 25,. 25) as
covariables.
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chemotherapy.37 Uncontrolled studies of HDT in patients with
recurrent ES describe some patients with far superior sur-
vival than would be expected from conventionally dosed che-
motherapy alone, but no randomized studies have been
conducted.39,40 It is possible that different induction regimens
may select different groups of patients for which the beneﬁts of
BuMel may also differ. Whether results similar to those reported
here are achievable with dose-compressed vincristine, doxoru-
bicin, cyclophosphamide/ifosfamide and etoposide is an open
question.2
As expected, more patients experienced severe toxicity in
the BuMel arm than in the VAI arm, mostly hematologic, di-
gestive, and hepatic. However, these types of toxicity were
transient and occurred only once after BuMel compared with
repetitive hematologic toxicity with VAI courses. Two patients
died as a result of BuMel toxicity, including one as a result of
interaction with radiotherapy. Recommendations for the use of
radiotherapy with BuMel as adopted during this study should
limit this risk. Long-term toxicity from this and similar cohorts
has yet to be reported.
These results are a further illustration of the value of in-
ternational collaboration in rare cancers such as ES. Although the
study was challenging to undertake, patients and their clinicians
can now beneﬁt from randomized evidence of the value of this
treatment. Although the beneﬁt was shown for a relatively small
subgroup, the reliable demonstration of EFS and OS improve-
ment indicates that BuMel may be considered as a standard of
care for patients with localized ES fulﬁlling the deﬁnition of
VAI 
More Toxic
BuMel
More Toxic
1010.1
Hematological toxicity
Infection
Liver toxicity
GI tract
General condition
Cardiac toxicity
Skin toxicity
Neurological toxicity
Renal toxicity
Lung toxicity
Haematuria/Bladder
VAI (n=116) BuMel (n=93)
100% 75% 75%50% 50%25% 25%0% 100%
All grades
Severe toxicity
All grades
Severe toxicity
Fig 3. Adverse events. The panel on the left is a butterﬂy plot showing the proportion of patients experiencing an adverse event, whatever the grade (gold for
busulfan andmelphalan [BuMel] and blue for the vincristine, dactinomycin, and ifosfamide [VAI] arm), and a severe adverse event (dark gold for BuMel and dark blue for
VAI arm) according to the randomization group. The panel on the right displays the relative risk of a severe adverse event in patients with BuMel relative to patients with
VAI, with 95% CIs for a 2 3 2 table. The acute toxicity related to chemotherapy was assessed after each course, using a list of 22 selected items from the National
Cancer Institute Common Toxicity Criteria version 2.0. A modiﬁed list of items was used to evaluate toxicity after radiotherapy, using Radiation Therapy Oncology
Group classiﬁcation for eight types of speciﬁc toxicities. A free text area was available to document other adverse reactions. The toxicity items were then pooled by
category: bladder toxicity, cardiac toxicity, GI toxicity, general deterioration, hematologic toxicity, infection, liver toxicity, lung toxicity, neurologic toxicity (including
mood alteration), renal toxicity, and skin toxicity. The respiratory tract toxicity (larynx, pharynx, salivary gland) reported after radiotherapy was pooled within the
category GI toxicity because of small numbers and because they were usually associated. Details are provided in the Data Supplement. For each adverse event type,
the analysis is based on the maximum grade observed over the whole maintenance treatment duration. A grade 4 hematologic toxicity and a grade $ 3 non-
hematologic toxicity were classiﬁed as severe toxicities. The categories of adverse event are ordered by decreasing value of the relative risk of severe toxicity. This
analysis was performed on the safety set (116 VAI patients and 93 BuMel patients), excluding patients who did not receive the treatment allocated by randomization,
similar to the as-treated population. The number of chemotherapy courses followed by toxicity over the whole maintenance treatment duration is detailed in the Data
Supplement.
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high-risk disease used in this trial and no contraindication to
BuMel.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS
OF INTEREST
Disclosures provided by the authors are available with this article at
jco.org.
AUTHOR CONTRIBUTIONS
Conception and design: Jeremy Whelan, Marie-Cecile Le Deley, Douglas
S. Hawkins, Stefan Burdach, Ruth Ladenstein, Jean Michon, Michael
Paulussen, Andreas Ranft, Hendrik van den Berg, Ian Lewis, Alan Craft,
Heribert Juergens
Administrative support: Marta Jimenez
Provision of study materials or patients: Uta Dirksen, Gwe´nae¨l Le Teuff,
Stefan Bielack, Jean-Yves Blay, Angelika Eggert, Hans Gelderblom,
Jean-Claude Gentet, Wolfgang Hartmann, Wolf-Achim Hassenpﬂug, Lars
Hjorth, Marta Jimenez, Thomas Klingebiel, Valerie Laurence, Perrine
Marec-Berard, Jean Michon, Michael Paulussen, Andreas Ranft, Hendrik
van den Berg, Ian Lewis, Alan Craft
Data analysis and interpretation: Jeremy Whelan, Marie-Cecile Le Deley,
Uta Dirksen, Gwe´nae¨l Le Teuff, Bernadette Brennan, Nathalie Gaspar,
Douglas S. Hawkins, Susanne Amler, Sebastian Bauer, Stefan Bielack, Jean-
Yves Blay, Stefan Burdach, Marie-Pierre Castex, Dagmar Dilloo, Hans
Gelderblom, Jean-Claude Gentet, Wolfgang Hartmann, Wolf-Achim
Hassenpﬂug, Lars Hjorth, Thomas Klingebiel, Udo Kontny, Jarmila
Kruseova, Ruth Ladenstein, Valerie Laurence, Cyril Lervat, Perrine Marec-
Berard, Sandrine Marreaud, Bruce Morland, Michael Paulussen, Andreas
Ranft, Peter Reichardt, Hendrik van den Berg, Keith Wheatley, Ian Judson,
Ian Lewis, Alan Craft, Heribert Juergens, Odile Oberlin
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
REFERENCES
1. Le Deley M-C, Paulussen M, Lewis I, et al:
Cyclophosphamide compared with ifosfamide in
consolidation treatment of standard-risk Ewing sar-
coma: Results of the randomized noninferiority Euro-
EWING99-R1 trial. J Clin Oncol 32:2440-2448, 2014
2. Womer RB, West DC, Krailo MD, et al: Ran-
domized controlled trial of interval-compressed
chemotherapy for the treatment of localized Ewing
sarcoma: A report from the Children’s Oncology
Group. J Clin Oncol 30:4148-4154, 2012 [Erratum: J
Clin Oncol 33:814, 2015]
3. Paulussen M, Craft AW, Lewis I, et al: Results
of the EICESS-92 Study: Two randomized trials of
Ewing’s sarcoma treatment–Cyclophosphamide
compared with ifosfamide in standard-risk patients
and assessment of beneﬁt of etoposide added to
standard treatment in high-risk patients. J Clin Oncol
26:4385-4393, 2008
4. Bacci G, Forni C, Longhi A, et al: Long-term
outcome for patients with non-metastatic Ewing’s
sarcoma treated with adjuvant and neoadjuvant
chemotherapies. 402 patients treated at Rizzoli be-
tween 1972 and 1992. Eur J Cancer40:73-83, 2004
5. Cotterill SJ, Ahrens S, Paulussen M, et al:
Prognostic factors in Ewing’s tumor of bone: Analysis
of 975 patients from the European Intergroup Co-
operative Ewing’s Sarcoma Study Group. J Clin
Oncol 18:3108-3114, 2000
6. Go¨bel V, Ju¨rgens H, Etspu¨ler G, et al: Prog-
nostic signiﬁcance of tumor volume in localized
Ewing’s sarcoma of bone in children and adoles-
cents. J Cancer Res Clin Oncol 113:187-191, 1987
7. Marina N, Granowetter L, Grier HE, et al: Age,
tumor characteristics, and treatment regimen as
event predictors in Ewing: A Children’s Oncology
Group report. Sarcoma 2015:927123, 2015
8. Oberlin O, Deley MC, Bui BN, et al: Prognostic
factors in localized Ewing’s tumours and peripheral
neuroectodermal tumours: The third study of the
French Society of Paediatric Oncology (EW88 study).
Br J Cancer 85:1646-1654, 2001
9. Paulussen M, Ahrens S, Dunst J, et al: Lo-
calized Ewing tumor of bone: Final results of the
cooperative Ewing’s Sarcoma Study CESS 86. J Clin
Oncol 19:1818-1829, 2001
10. Bacci G, Ferrari S, Bertoni F, et al: Prognostic
factors in nonmetastatic Ewing’s sarcoma of bone
treated with adjuvant chemotherapy: Analysis of 359
patients at the Istituto Ortopedico Rizzoli. J Clin Oncol
18:4-11, 2000
11. Le Deley MC, Ahrens S, Paulussen M, et al:
Histological response is the main prognostic factor of
survival in localised Ewing tumor treated with che-
motherapy alone before surgery. International Soci-
ety of Pediatric Oncology (SIOP). Brisbane. Pediatr
Blood Cancer 85:1646-1654, 2001
12. Cornbleet MA, Corringham RE, Prentice HG,
et al: Treatment of Ewing’s sarcoma with high-dose
melphalan and autologous bone marrow trans-
plantation. Cancer Treat Rep 65:241-244, 1981
13. Hartmann O, Benhamou E, Beaujean F, et al:
High-dose busulfan and cyclophosphamide with au-
tologous bone marrow transplantation support in ad-
vanced malignancies in children: A phase II study.
J Clin Oncol 4:1804-1810, 1986
14. Hartmann O, Oberlin O, Beaujean F, et al: Role
of high-dose chemotherapy followed by bone mar-
row autograft in the treatment of metastatic Ewing’s
sarcoma in children [in French]. Bull Cancer 77:181-
187, 1990
15. Burdach S, Ju¨rgens H, Peters C, et al: Mye-
loablative radiochemotherapy and hematopoietic
stem-cell rescue in poor-prognosis Ewing’s sarcoma.
J Clin Oncol 11:1482-1488, 1993
16. Ladenstein R, Lasset C, Pinkerton R, et al:
Impact of megatherapy in children with high-risk
Ewing’s tumours in complete remission: A report
from the EBMT Solid Tumour Registry. BoneMarrow
Transplant 15:697-705, 1995 [Erratum: BoneMarrow
Transplant 15:697-705, 1995]
17. Atra A, Whelan JS, Calvagna V, et al: High-
dose busulphan/melphalanwith autologous stem cell
rescue in Ewing’s sarcoma. BoneMarrow Transplant
20:843-846, 1997
18. Ladenstein R, Hartmann O, Pinkerton R, et al:
A multivariate and matched pair analysis on high-risk
Ewing tumor (ET) patients treated by megatherapy
(MGT) and stem cell reinfusion (SCR) in Europe. Proc
Am Soc Clin Oncol 18:555, 1999 (abstr)
19. Ferrari S, Sundby Hall K, Luksch R, et al:
Nonmetastatic Ewing family tumors: High-dose
chemotherapy with stem cell rescue in poor re-
sponder patients. Results of the Italian Sarcoma
Group/Scandinavian Sarcoma Group III protocol. Ann
Oncol 22:1221-1227, 2011
20. Gaspar N, ReyA, Be´rard PM, et al: Risk adapted
chemotherapy for localised Ewing’s sarcoma of bone:
The French EW93 study. Eur J Cancer 48:1376-1385,
2012
21. Juergens C, Weston C, Lewis I, et al: Safety
assessment of intensive induction with vincristine,
ifosfamide, doxorubicin, and etoposide (VIDE) in
the treatment of Ewing tumors in the EURO-
E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 47:
22-29, 2006
22. Ladenstein R, Po¨tschger U, Le Deley MC,
et al: Primary disseminated multifocal Ewing sar-
coma: Results of the Euro-EWING 99 trial. J Clin
Oncol 28:3284-3291, 2010
23. Toxicity of high-dose chemotherapy (busulfan-
melphalan) followed by radiation therapy (RT) in
Ewing’s axial tumours: Results of the French study.
in International Society of Paediatric Oncology (SIOP).
Pediatr Blood Cancer 49:555, 2007 (abstr)
24. Strauss SJ,McTiernan A, Driver D, et al: Single
center experience of a new intensive induction therapy
for Ewing’s family of tumors: Feasibility, toxicity, and
stem cell mobilization properties. J Clin Oncol 21:
2974-2981, 2003
25. Bearman SI, Anderson GL, Mori M, et al:
Venoocclusive disease of the liver: Development of
a model for predicting fatal outcome after marrow
transplantation. J Clin Oncol 11:1729-1736, 1993
26. RTOG Foundation: RTOG/EORTC Late Radia-
tion Morbidity Scoring Schema. https://www.rtog.
org/ResearchAssociates/AdverseEventReporting/
RTOGEORTCLateRadiationMorbidityScoringSchema.
aspx
27. Freedman LS: Tables of the number of pa-
tients required in clinical trials using the logrank test.
Stat Med 1:121-129, 1982
28. Lan KG, DeMets DL: Discrete sequential
boundaries for clinical trials. Biometrika 70:659-663,
1983
29. O’Brien PC, Fleming TR: A multiple testing
procedure for clinical trials. Biometrics 35:549-556,
1979
30. McTiernan AM, Cassoni AM, Driver D, et al:
Improving outcomes after relapse in Ewing’s sar-
coma: Analysis of 114 patients from a single in-
stitution. Sarcoma 2006:83548, 2006
31. Wassmer G: Planning and analyzing adaptive
group sequential survival trials. Biom J 48:714-729,
2006
32. Kalbﬂeisch J, Prentice R: The Statistical
Analysis of Failure Time Data (ed 2). New York, NY,
Wiley, 2002
3118 © 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Whelan et al
33. Fine JP, Gray R: A proportional hazards model
for the subdistribution of a competing risk. J Am Stat
Assoc 94:496-509, 1999
34. Cherny NI, Sullivan R, Dafni U, et al: A stand-
ardised, generic, validated approach to stratify the
magnitude of clinical beneﬁt that can be anticipated
from anti-cancer therapies: The European Society for
Medical Oncology Magnitude of Clinical Beneﬁt Scale
(ESMO-MCBS). Ann Oncol 26:1547-1573, 2015
35. Gaspar N, Hawkins DS, Dirksen U, et al: Ewing
sarcoma: Current management and future approaches
through collaboration. J ClinOncol 33:3036-3046, 2015
36. Luksch R, Tienghi A, Hall KS, et al: Primary
metastatic Ewing’s family tumors: Results of the
Italian Sarcoma Group and Scandinavian Sarcoma
Group ISG/SSG IV Study including myeloablative
chemotherapy and total-lung irradiation. Ann Oncol
23:2970-2976, 2012
37. Whelan JS, Burcombe RJ, Janinis J, et al: A
systematic review of the role of pulmonary irradiation
in the management of primary bone tumours. Ann
Oncol 13:23-30, 2002
38. Razek A, Perez CA, Tefft M, et al: Intergroup
Ewing’s Sarcoma Study: Local control related to radiation
dose, volume, and site of primary lesion in Ewing’s
sarcoma. Cancer 46:516-521, 1980
39. Barker LM, Pendergrass TW, Sanders JE,
et al: Survival after recurrence of Ewing’s sarcoma
family of tumors. J Clin Oncol 23:4354-4362, 2005
40. Rasper M, Jabar S, Ranft A, et al: The value of
high-dose chemotherapy in patients with ﬁrst re-
lapsed Ewing sarcoma. Pediatr Blood Cancer 61:
1382-1386, 2014
41. Lin DY, Wei L-J, Ying Z: Checking the Cox
model with cumulative sums of martingale-based
residuals. Biometrika 80:557-572, 1993
Affiliations
Jeremy Whelan, University College Hospital; Ian Judson, Institute of Cancer Research, London; Bernadette Brennan, Royal
Manchester Children’s Hospital, Manchester; Bruce Morland, Birmingham Children’s Hospital; Keith Wheatley, University of
Birmingham, Birmingham; Ian Lewis, Leeds Community Healthcare National Health Service Trust, Leeds; Alan Craft, Newcastle
University, Newcastle upon Tyne, United Kingdom; Marie-Cecile Le Deley and Cyril Lervat, Centre Oscar Lambret, Lille; Gwe´nae¨l Le
Teuff, Nathalie Gaspar, and Odile Oberlin, Institut Gustave Roussy, Villejuif; Jean-Yves Blay, Centre Le´on Be´rard; Perrine Marec-
Berard, Institute of Pediatric Onco-Haematology, Lyon; Marie-Pierre Castex, Centre Hospitalier Universitaire de Toulouse, Toulouse;
Jean-Claude Gentet, Centre Hospitalier Universitaire La Timone, Marseille; Marta Jimenez, Unicancer; Valerie Laurence and Jean
Michon, Institut Curie, Paris; France; Uta Dirksen, Sebastian Bauer, Andreas Ranft, University Hospital Essen, Essen; Susanne Amler,
Institut fu¨r Biometrie und Klinische Forschung; Wolfgang Hartmann and Heribert Juergens, Universita¨tsklinikum, Mu¨nster, Mu¨nster;
Stefan Bielack, Klinikum Stuttgart, Stuttgart; Stefan Burdach, Comprehensive Cancer Center, Mu¨nchen; Dagmar Dilloo, University-
Clinic Bonn, Bonn; Angelika Eggert, Charite´ University; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Wolf-Achim
Hassenpﬂug, University Medical Center Hamburg-Eppendorf, Hamburg; Thomas Klingebiel, Childrens University Hospital,
Frankfurt; Udo Kontny, University Medical Center Aachen, Aachen; Michael Paulussen, Children’s and Adolescents’ Hospital,
Datteln; Germany; Douglas S. Hawkins, Seattle Children’s Hospital, Seattle, WA; Hans Gelderblom, Leiden University Medical
Center, Leiden; Hendrik van den Berg, University of Amsterdam, Amsterdam, the Netherlands; Lars Hjorth, Skane University
Hospital, Lund, Sweden; Jarmila Kruseova, Faculty Hospital Motol Prague, Prague, Czech Republic; Ruth Ladenstein, St Anna
Children’s Hospital and Children’s Cancer Research Institute, Vienna, Austria; Sandrine Marreaud, European Organisation for
Research and Treatment of Cancer, Brussels, Belgium
Support
Euro-E.W.I.N.G.99 is an academic clinical trial funded through multiple national and international government agencies and cancer
charities: FP7-EURO EWING Consortium; Germany: Deutsche Krebshilfe (Grants No. 70-2551-Jue3 and 108128), and Bundesministerium
fu¨r Bildung und Forschung (Grants No. BMBF 01GM0869 and BMBF/Era-Net 01KT1310); France: Association Enfants et Sante´, Socie´te´
Française de Lutte Contre les Cancers et les Leuce´mies de l’Enfant et de l’Adolescent, Unicancer; United Kingdom: Cancer Research UK (Grant
No. CRUK/02/014), National Institute for Health Research University College London Hospitals Biomedical Research Centre.
Prior Presentation
Presented at the ASCOAnnual Meeting, Chicago, IL, June 3 to 7, 2016; and the Connective Tissue Oncology Society Annual Meeting,
Lisbon, Portugal, November 9 to 12, 2006.
n n n
jco.org © 2018 by American Society of Clinical Oncology 3119
High-Dose Chemotherapy for Ewing Sarcoma
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing
Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are
self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more
information about ASCO’s conﬂict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.
Jeremy Whelan
No relationship to disclose
Marie-Cecile Le Deley
No relationship to disclose
Uta Dirksen
Consulting or Advisory Role: Eli Lilly (Inst)
Travel, Accommodations, Expenses: Jazz Pharmaceuticals
Gwe´nae¨l Le Teuff
No relationship to disclose
Bernadette Brennan
Travel, Accommodations, Expenses: Jazz Pharmaceuticals
Nathalie Gaspar
Travel, Accommodations, Expenses: EISAI
Douglas S. Hawkins
Travel, Accommodations, Expenses: Loxo, Bayer, Bristol-Myers Squibb,
Celgene
Susanne Amler
No relationship to disclose
Sebastian Bauer
Honoraria: Novartis, Pﬁzer, Bayer, Pharmamar, GlaxoSmithKline
Consulting or Advisory Role: Blueprint Medicines, Bayer, Eli Lilly,
Deciphera, Nanobiotix
Research Funding: Blueprint Medicines, Novartis, Incyte (Inst)
Travel, Accommodations, Expenses: Pharmamar
Stefan Bielack
Consulting or Advisory Role: Clinigen Group, Bayer, Eli Lilly, Pﬁzer,
Novartis, Isofol Medical, Sensorion
Research Funding: Janssen-Cilag (Inst), Amgen (Inst), EISAI (Inst), Loxo
Jean-Yves Blay
No relationship to disclose
Stefan Burdach
Stock or Other Ownership: PDLI
Marie-Pierre Castex
No relationship to disclose
Dagmar Dilloo
Stock or Other Ownership: Pﬁzer, Amgen (I), Johnson & Johnson,
Merck (I)
Angelika Eggert
No relationship to disclose
Hans Gelderblom
No relationship to disclose
Jean-Claude Gentet
No relationship to disclose
Wolfgang Hartmann
Travel, Accommodations, Expenses: Menarini
Wolf-Achim Hassenpﬂug
Consulting or Advisory Role: Shire, CSL Behring, SOBI
Travel, Accommodations, Expenses: Shire, Novo Nordisk
Lars Hjorth
Stock or Other Ownership: Bioinvent
Marta Jimenez
No relationship to disclose
Thomas Klingebiel
No relationship to disclose
Udo Kontny
Consulting or Advisory Role: Eisai
Jarmila Kruseova
No relationship to disclose
Ruth Ladenstein
Honoraria: Apeiron Biologics, Boehringer Ingelheim, EUSA Pharma
Consulting or Advisory Role: Apeiron Biologics, Boehringer Ingelheim,
EUSA Pharma (Inst)
Research Funding; Apeiron Biologics (Inst), EUSA Pharma (Inst)
Patents, Royalties, Other Intellectual Property: Apeiron Biologics (Inst)
Expert Testimony: Apeiron Biologics, EUSA Pharma
Travel, Accommodations, Expenses: Apeiron Biologics, EUSA Pharma
Valerie Laurence
No relationship to disclose
Cyril Lervat
Travel, Accommodations, Expenses: Chugai Pharma
Perrine Marec-Berard
No relationship to disclose
Sandrine Marreaud
No relationship to disclose
Jean Michon
Travel, Accommodations, Expenses: Bristol-Myers Squibb
Bruce Morland
Consulting or Advisory Role: Bayer. Clinigen Group
Michael Paulussen
No relationship to disclose
Andreas Ranft
No relationship to disclose
© 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Whelan et al
Peter Reichardt
Honoraria: Novartis, Pﬁzer, Bayer, PharmaMar, Eli Lilly, GSK, Amgen
Consulting or Advisory Role: GSK, Novartis, Clinigen Group, Eli Lilly,
Merck, Bayer, Roche, BMS
Research Funding: Novartis (Inst)
Hendrik van den Berg
No relationship to disclose
Keith Wheatley
Research Funding: Novartis (Inst)
Ian Judson
Honoraria: Eli Lilly
Consulting or Advisory Role: Eli Lilly
Research Funding: AstraZeneca (Inst)
Patents, Royalties, Other Intellectual Property: Rewards to inventors
relating to patent for abiraterone acetate
Travel, Accommodations, Expenses: Eli Lilly
Ian Lewis
No relationship to disclose
Alan Craft
No relationship to disclose
Heribert Juergens
No relationship to disclose
Odile Oberlin
No relationship to disclose
jco.org © 2018 by American Society of Clinical Oncology
High-Dose Chemotherapy for Ewing Sarcoma
Acknowledgment
We are indebted to all the patients and parents who agreed to participate in this study; Carolyn Douglas, Sue Ablett, Paul Donachie,
Children’s Cancer and Leukaemia Group Data Centre, Leicester, United Kingdom; Davina Scott, Jennifer Anderton, Nicola Fenwick, Keith
Wheatley, Veronica Moroz, Cancer Research UK Clinical Trials Unit, University of Birmingham, United Kingdom; Susanne Ahrens,
Martina Blankscha¨n, Gabriele Braun-Munzinger, Susanne Jabar, Andreas Ranft, Gesellschaft fu¨r Pa¨diatrische Onkologie und Ha¨matologie
data center, Mu¨nster, Germany; Eva Sorz, Austrian-Gesellschaft fu¨r Pa¨diatrische Onkologie und Ha¨matologie data center, Vienna, Austria;
Anthony Mangin, Jean-François Leforestier, Yulia Belikova, Noel Ny Tovo, Zakia Idir, Fatima Bizeul, Julien Marandet, Muriel Wartelle,
Nathalie Cozic, Institut Gustave Roussy, Villejuif; Marta Jimenez, Ce´line Mahier Aı¨t Oukhatar, Naı¨ma Bonnet, Jessy Delaye, Jean Gene`ve,
Unicancer, Paris, France; Christine Olungu, Anne Kirkpatrick, Saskia Litiere, SandrineMarreaud, European Organization for Research and
Treatment of Cancer data center, Brussels, Belgium, for data management and study coordination assistance; Robert Souhami, Paul
Meyers, and Abdel Babiker for participating in the Independent Data Monitoring Committee; and all investigators who participated in the
trial.
Appendix
All investigators who participated in the trial:
From Austria: Ch. Urban, University Children’s Hospital, Graz; B. Meister and F.M. Fink, University Children’s Hospital,
Innsbruck; R. Kerbl, Leoben Clinical Centre, Children’s Hospital Leoben; O. Stollinger, Children’s Hospital Barmherzige
Schwestern, Linz; K. Schmitt and G. Ebetsberger, Linz Clinical Centre, Children’s Hospital, Linz; N. Jones, University Hospital,
Salzburg, R. Ladenstein and H. Gadner, St Anna Children’s Hospital, Wien; B. Ausserer, Children`s Hospital, Dornbirn;
From Belgium: P. Maes, AZM Children’s Cancer Centre, Antwerpen; B. Brichard, University Children’s Hospital, Brussels; F.
Mazzeo, University Hospital, Clinical Oncology, Brussels; T. Gil, Hoˆpitaux universitaires Bordet-Erasme, Brussels; C. Dhooge,
Universitair Ziekenhuis, Gent; J.B. Vermorken, Universitair Ziekenhuis, Antwerpen; A. Klein, Hoˆpital Universitaire des Enfants
Reine Fabiola, Brussels;
From Czech Republic: J. Kruseova, University Hospital Motol, Prague;
From Denmark: A. Krarup-Hansen, Herlev Hospital-University, Copenhagen; O. Nielsen, Aarhus University Hospital, Aarhus;
From Ireland: M. Capra, Our Lady’s Children’s Hospital, Dublin;
From Finland: J. Kanerva, Pediatric Oncology, Helsinki University Children’s Hospital, Helsinki, Finland;
From France: C. Devoldere, University Hospital, Amiens; I. Pellier, University Hospital, Angers; O. Collard, Institut de
Cancerologie de l’Ouest, Saint Priest en Jarez; P. Soulie, Centre Paul Papin, Angers; E. Plouvier, University Hospital, Besançon; C.
Ve´rite´, University Hospital, Bordeaux; B. Bui N’guyen, Institut Bergonie´, Bordeaux; G. Dabouis, University Hospital, Nantes; F.
Aubier, Hoˆpital d’enfants Margency, Margency; O. Minckes, University Hospital, Caen; C. Delcambre, Centre François Baclesse,
Caen; J.O. Bay, Centre Jean Perrin, Clermont-Ferrand; J. Kanold, University Hospital, Clermont-Ferrand; E. Colomb, University
Hospital, Dijon; N. Isambert, Centre Jean François Leclerc, Dijon; D. Plantaz, University Hospital, Grenoble; A.S Defachelles,
Centre Oscar Lambret, Lille; C. Piguet, University Hospital, Limoges; P. Marec-Be´rard, Centre Le´on Be´rard, Lyon; J.Y. Blay, Centre
Le´on-Be´rard, Lyon; J.C. Gentet, University Hospital, Marseille; F. Duffaud, University Hospital, Marseille; F. Bertucci, Institut Paoli
Calmettes, Marseille; J.P Lotz, Hoˆpital Tenon, Paris; L. Saumet, University Hospital, Montpellier; C. Schmitt, University Hospital,
Nancy; M. Rios, Centre Alexis Vautrin, D. Cupissol, Institut du Cancer de Montpellier, Val d’Aurelle, Montpellier; Nancy; N.
Corradini, University Hospital, Nantes; F. Rolland, Centre Rene´ Gauducheau, Nantes; A. Deville, University Hospital, Nice; A.
Thyss, Centre Antoine Lacassagne, Nice; J. Michon, Institut Curie, Paris; M.D. Tabone, Trousseau University Hospital, Paris; V.
Laurence, Institut Curie, Paris; F. Millot, University Hospital, Poitiers; S. Gorde GrosJean, University Hospital, Reims; S. Taque,
University Hospital, Rennes; J.P. Vannier, University Hospital, Rouen; C. Guillemet, Centre Henri Becquerel, Rouen; L. Chauvenet,
Hotel Dieu, Paris; E. Brain, Centre Rene´ Huguenin, St Cloud; C. Berger, University Hospital, St Etienne; P. Lutz, University Hospital,
Strasbourg; M.P. Castex, University Hospital, Toulouse; H. Roche, Institut Claudius Regaud, Toulouse; O. Lejars, University
Hospital, Tours; C. Linassier, University Hospital, Tours; O. Oberlin, Institut Gustave Roussy, Villejuif; N. Gaspar, Institut Gustave
Roussy, Villejuif; A. Le Cesne, Institut Gustave Roussy, Villejuif;
From Germany (EORTC): S. Bauer, P. Ebeling, and M. Flasshove, Essen University Hospital, Essen; J.T. Hartmann, Eberhard
Karls University, Tuebingen; P. Reichardt, Charite´ Universitaetsmedizin, Campus Berlin- Bush, Berlin
From Germany (GPOH): R. Mertens, U. Kontny, University Children’s Hospital, Aachen; R. Osieka, University Hospital,
Medical Oncology, Aachen; A. Gnekow, Augsburg Clinical Centre, Children’s Hospital, Augsburg; G. Schlimok, Medical Oncology,
Augsburg Clinical Centre, Augsburg; G. Henze, P. Hundsdo¨rfer, Charite´ Virchow Clinical Centre, Children’s Hospital, Berlin; P.
© 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Whelan et al
Thuss-Patience, A. Kunitz, Charite´ Virchow Clinical Centre, Berlin; L. Wickmann, L. Schweigerer, Berlin-Buch Children’s Hospital,
Berlin; P. Reichardt, Medical Oncology, Berlin-Buch Clinical Centre, Berlin; K. Possinger, Medical Oncology, Charite´ Central
Campus, Berlin; J. Potenberg, Ev. Waldkrankenhaus, Berlin; P. Reichardt, Charite´ Universitaetsmedizin, Campus Berlin-Buch,
Berlin; N. Jorch, Ev. Children’s Hospital Bielefeld; U. Kru¨mpelmann, Medical Oncology Ev. Hospital, Bielefeld; H. Weh, Medical
Oncology, Franziskus Hospital, Bielefeld; J. Baier, Medical Oncology, St Josef ’s Hospital, Bochum;W. Schmiegel, Medical Oncology,
Ruhr-University Hospital, Bochum; U. Bode, D. Dilloo, University Children’s Hospital, Bonn; I.G.M. Schmidt-Wolf, V. Janzen,
Medical Oncology I, University Hospital Bonn; J. Nolting, University Hospital, Medical Oncology III, Bonn; W. Eberl, Children’s
Hospital, Braunschweig; B. Wo¨rmann, Medical Oncology, City Hospital, Braunschweig; W. Hoffmann, Radiology and Radio-
therapy, City Hospital, Braunschweig; Th. Wolff, J. Kullmer, Ev. Diakonie Hospital, Bremen; A. Pekrun, Bremen Mitte Children’s
Hospital, Bremen; A. Hofmann, Children’s Hospital, Chemnitz; G. Geißler, Internal Medicine III, Chemnitz; E. Hohlfeld; Carl-
Thiem-Hospital, Cottbus; W. Andler, T. Wiesel, Children’s Hospital, Datteln; D. Schneider, B. Bernbeck, Children’s Hospital,
Dortmund; I. Lauterbach, M. Suttorp, University Children’s Hospital, Dresden; S. Richter, G. Ehninger, University Hospital
Dresden; P. Zickler, Children’s Hospital, Duisburg; U. Go¨bel, A. Borkhardt, University Children’s Hospital, Du¨sseldorf; J.-N.
Machatschek, Medical Oncology, University Hospital, Du¨sseldorf; A. Lemmer, A. Sauerbrey, Children’s Hospital, Erfurt; W. Holter,
M. Metzler, University Children’s Hospital, Erlangen; N. Meidenbauer, University Hospital, Erlangen; S. Seeber, S. Bauer, P. Ebeling,
and M. Flasshove, University Hospital, Essen; A. Eggert, G. Fleischhack, University Children’s Hospital, Essen; T. Klingebiel,
University Children’s Hospital Frankfurt, M. Ahrens University Hospital Frankfurt; C. Niemeyer, J. Ro¨ßler, University Children’s
Hospital, Freiburg; J. Heinz, Medical Oncology, University Hospital, Freiburg; A. Reiter, W. Wo¨ssmann University Children’s
Hospital, Giessen; M. Rummel, W. Blau, Medical Oncology, University Hospital, Giessen; V. Runde, Goch Clinical Centre, Goch;
M. Lakomek, C. Kramm University Children’s Hospital, Go¨ttingen; L. Tru¨mper, D. Hertramph, Medical Oncology, University
Hospital, Go¨ttingen; J. Beck, H. Lode University Children’s Hospital, Greifswald; G. Do¨lken, Medical Oncology, University
Hospital, Greifswald; H.-W. Lindemann, Hagen Clinical Centre, Hagen; G. Gu¨nther, D. Ko¨rholz, T. Bernig, University Children’s
Hospital, Halle; H.-J. Schmoll, Medical Oncology, University Hospital, Halle; R. Schneppenheim, W.A. Hassenpﬂug, UKE
University Children’s Hospital, Hamburg; D.K. Hossfeld, C. Bokemeyer, Medical Oncology, UKE University Hospital, Hamburg;
W. Alberti, Radiology and Radiotherapy, UKE University Hospital, Hamburg; H. Keles, Medical Oncology, Asklepios Hospital Altona,
Hamburg; N. Schmitz, Haematology, Asklepios Hospital St Georg, Hamburg; N. Bru¨llke, Medical Oncology, Asklepios Hospital
Barmbek, Hamburg; H. Schmidt, Internal Medicine, Regional Hospital, Hameln; C. Du¨rk, Medical Oncology, St Marien Hospital,
Hamm; K. Welte, C. Klein, B. Maecker-Kohlhoff, Pediatric Oncology, Hannover Medical School, Hannover; Ch. Reuter, Medical
Oncology, Hannover Medical School, Hannover; H. Kirchner, Medical Oncology III, Siloah Hospital, Hannover; A. Kulozik,
W. Behnisch, University Children’s Hospital, Heidelberg; G. Egerer, Medical Oncology, University Hospital, Heidelberg; Ewerbeck,
Orthopedic, University Hospital, Heidelberg; M. Thomas, Medical Oncology, Thorax Hospital, Heidelberg; J. Cyran, Clinical
Centre, Heilbronn; Kachel, Pediatrics, SLK Hospital, Heilbronn; U. Martens, Pediatric, Haematology, SLK Hospital Heilbronn; Ch.
Tautz, General Hospital, Herdecke; D. Strumberg, St Marien Hospital, Herne; W. Freier, Oncology Practice, Hildesheim; U. Kaiser,
Medical Oncology II, St Bernward, Hildesheim; N. Graf, University Children’s Hospital, Homburg; M. Pfreundschuh, Medical
Oncology, University Hospital, Homburg; F. Zintel, B. Gruhn, University Children’s Hospital, Jena; E. Eigendorff, University
Hospital, Jena; H. Link, Medical Oncology, Westpfalz Hospital, Kaiserslautern; R. Germann, A. Leipold, Children’s Hospital,
Karlsruhe; Th. Fischer, M. Bentz, Medical Oncology, Karlsruhe Clinical Centre, Karlsruhe; J. Mezges, Medical Oncology, St
Vincentius Hospital, Karlsruhe; H. Wehinger, M. Nathrath, Children’s Hospital, Kassel; M. Wolf, Medical Oncology, Kassel
Hospital, Kassel; H. Meye, Radiotherapy, Kassel Hospital, Kassel; Pru¨mmer, Internal Medicine III, Kempten Ober-Allga¨u Hospital,
Kempten; M. Schrappe, A. Claviez, University Children’s Hospital, Kiel; M. Lamprecht, Medical Oncology II, University Hospital,
Kiel; H. Nolte, Kemperhof Clinical Centre, Koblenz; M. Rister, M. Jakob, Kemperhof Koblenz, Koblenz; F. Berthold, T. Simon,
University Children’s Hospital, Cologne; V. Diehl, J. Wolf, Medical Oncology, University Hospital, Cologne; W. Sternschulte,
A. Prokop, Children’s Hospital, Cologne; E. Stoelben, Pulmonary Hospital, Cologne; S. Voelpel, T. Imschweiler, Children’s Hospital,
Krefeld; T. Frieling, Medical Oncology, Krefeld Clinical Centre, Krefeld; J. Moessner, D. Niederwiese, Medical Oncology, University
Hospital, Leipzig; U. Bierbach, H. Christiansen, University Children’s Hospital, Leipzig; J. Bennek, Pediatric Surgery, University
Hospital, Leipzig; L. Mantovani, Medical Oncology, St Georg Hospital, Leipzig; D. Selle, St Annastift Children’s Hospital, Lud-
wigshafen; P. Bucsky, T. Langer, University Children’s Hospital, Lu¨beck; H. Bartels, Medical Oncology, Clinical Centre Lu¨beck
South, Lu¨beck; Th. Wagner, Medical Oncology I, University Hospital, Lu¨beck; G. Heil, Medical Oncology, Reginal Hospital,
Lu¨denscheid; M. Mohren, Th. Fischer, E. Schalk, Medical Oncology, University Hospital, Magdeburg; U. Kluba, P. Vorwerk,
University Children’s Hospital, Magdeburg; P. Gutjahr, M. Dittrich, J. Faber, University Children’s Hospital, Mainz; H.-J. Beck,
Medical Oncology III, University Hospital, Mainz; S. Reiter, B. Kasper, Medical Oncology III, University Hospital, Mannheim;
jco.org © 2018 by American Society of Clinical Oncology
High-Dose Chemotherapy for Ewing Sarcoma
M. Du¨rken, University Children’s Hospital, Mannheim; A. Neubauer, J. Beyer, Medical Oncology, University Hospital, Marburg;
B. Schu¨tz, H. Christiansen, University Children’s Hospital, Marburg; B. Erdlenbruch, Pediatrics Johannes Wesling Hospital,
Minden; M. Griesshammer, Medical Oncology, Johannes Wesling Hospital, Minden; Reis, Medical Oncology, St,. Franziskus
Hospital, Mo¨nchengladbach; S. Burdach, A. Wawer, TU Technical University (TU) Clinical Centre, Children’s Hospital, Mu¨nchen;
I. Schmid, Ludwig-Maximilians-University (LMU) Children’s Hospital, Munich; C. Meyer zum Bu¨schenfelde, C. Peschel,
S. Lorenzen, Medical Oncology, TU Clinical Centre, Munich; B. Emmerich, M. Schlemmer, F. Oduncu, R. Issels, Medical Oncology,
LMU Clinical Centre, Munich; H. Ju¨rgens, University Children’s Hospital, Mu¨nster; W. Berdel, A. Kerkhoff, Medical Oncology,
University Hospital, Mu¨nster; H. Held, Medical Oncology, Clinical Centre, Neumu¨nster; G. Hofmann-Wackersreuther,
W. Scheurlen, M. Augustin, Medical Oncology, Clinical Centre, Nu¨rnberg; H. Mu¨ller, Children’s Hospital, Oldenburg; C.-H. Ko¨hne,
D. Kra¨mer, Medical Oncology, Oldenburg Hospital, Oldenburg; A. Rickers, Pediatrics, Marienhospital, Osnabru¨ck; T. Wolff,
Medical Oncology, St Josef Hospital, Paderborn; U. Loss, Internal Medicine, Knappschaftshorpital, Recklinghausen; O. Peters, St
Hedwig Children’s Hospital, Regensburg; R. Andreesen, S. Krause, M. Grube, Medical Oncology, University Hospital, Regensburg;
Kreuser, Medical Oncology, Barmherzige Bru¨der Hospital, Regensburg; S. Corbacioglu, University Children’s Hospital, Regensburg;
C.-F. Classen, University Children’s Hospital, Rostock; M. Freund, Medical Oncology, University Hospital Rostock; J. Potratz,
F. Heits, Medical Oncology, Rotenburg Clinical Centre, Rotenburg; R. Geib-Ko¨nig, Winterberg Clinical Centre, Children’s Hospital,
Saarbru¨cken; J. Weis, Radiology and Radiotherapy, Saarbrcken Hospital, Saarbru¨cken; M. Kasbohm, Helios Clinical Centre,
Children’s Hospital, Schwerin; D. Ha¨hling, Medical Oncology, Helios Hospital, Schwerin; D. Bu¨rger, R. Burghard, Deutsches Rotes
Kreuz Children’s Hospital, Siegen; R. Dickerhoff, H. Reinhard, Asklepios Clinical Centre, Children’s Hospital, St Augustin;
S. Bielack, K. Apel, S. Simon-Klingenstein, Stuttgart Cancer Center, Pediatrics 5 (Oncology, Hematology, Immunology), Klinikum
Stuttgart – Olgahospital, Stuttgart; H.G. Mergenthaler, G. Illerhaus, Stuttgart Cancer Center, Medical Oncology, Klinikum Stuttgart -
Katharinenhospital, Stuttgart; C. Denzlinger, Internal Medicine III, Marienhospital, Stuttgart; I. Feddersen, S. Weis, Rauh
Mutterhaus der Borroma¨erinnen, Children’s Hospital, Trier; M.R. Clemens, Hospital “Barmherzige Bru¨der”, Trier; Waladkhani,
Medical Oncology I, Mutterhaus der Borroma¨erinnen, Trier; H. Kirchen, Medical Oncology, Barmherzige Bru¨der Hospital, Trier;
R. Handgretinger, M. Ebinger, University Children’s Hospital, Tu¨bingen; Brossart, J.T. Hartmann, H.-G. Kopp, Eberhard Karls
Universitaet, Tuebingen; ; K.-M. Debatin, University Children’s Hospital, Ulm; Do¨hner, R. Mayer-Steinacker, University Cancer
Centre, Ulm; M. Mu¨ller, A. Schoengen, Internal Medicine I, Bundeswehrkrankenhaus, Ulm; St Brettner, Medical Oncology,
Regional Hospital, Waldbro¨hl; N. Frickhofen, Internal Medicine III, Dr.-Horst-Schmidt-Hospital, Wiebaden; Dohrn, Pediatrics,
HELIOS Hospital, Wuppertal; M. Sandmann, Medical Oncology, St Antonius Hospital, Wuppertal; P. Schlegel, University
Children’s Hospital, Wu¨rzburg;
From Hong Kong: V. Lee and K-W Chik, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong;
From Hungary: P. Hauser, Semmelweis University Children’s Hospital, Budapest, Hungary;
From the Netherlands: H. van den Berg, AMC Emma Children’s Hospital/Academic Medical Centre, Amsterdam;
S. Rodenhuis, The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam; A.J. Gelderblom, J. Anninga,
Leiden University Medical Centre, Cancer Centre, Leiden; P. Hoogerbrugge and JPM. Bo¨kkerink, UMC St Radboud, Nijmegen;
R. Pieters, Sophia Children’s Hospital - Erasmus Medical Centre, Rotterdam;
From New Zealand: R, Corbett, Christchurch Hospital, Christchurch
From Sweden: G. O¨sterlundh, Queen Silvia’s Children’s Hospital, Sahlgrenska Hospital, Gothenburg; M. Behrendtz and B.-M.
Holmqvist, Department of pediatrics, Linko¨ping University Hospital, Linko¨ping; L. Hjorth, Children’s Hospital, Ska˚ne University
Hospital, Lund; C. Petersen and A˚. Jakobson, Astrid Lindgren’s Children’s Hospital, Karolinska Hospital, Stockholm; U. Hjalmars,
Department of pediatrics, Umea˚ University Hospital, Umea˚; G. Ljungman, Academic Children’s Hospital, Academic Hospital,
Uppsala;
From Switzerland: R. Angst, Kantonsspital Aarau; T. Ku¨hne andM. Paulussen, University Children’s Hospital, Basel; S. Leyvraz,
Lausanne Cancer Centre, Lausanne; J. Rischewski, Luzerner Kantonsspital, Luzern; A. Feldges and J. Greiner, Ostschweizer
Kinderspital, St Gallen, U. Hess, Clinical Centre, Medical Oncology, S. Gallen; G.U. Exner, Orthopedic Hospital Balgrist, Zu¨rich;
F. Niggli, University Children’s Hospital, Zu¨rich; A. Knuth, University Hospital, Medical Oncology, Zu¨rich;
From United Kingdom: D. King and H. Bishop, Royal Aberdeen Children’s Hospital, Aberdeen; A. McCarthy, Royal Belfast
Hospital for Sick Children, Belfast; P. Henry, Belfast City Hospital, Belfast; B. Morland, Birmingham Children’s Hospital, Bir-
mingham; H. Rees, University Hospitals Bristol NHS Foundation Trust, Bristol; J. Nicholson, Addenbrooke’s Hospital, Cambridge;
H. Traunecker, Children’s Hospital for Wales, Cardiff; H. Wallace, Royal Hospital for Sick Children, Edinburgh; M. Ronghe and
E. Simpson, Royal Hospital for Sick Children, Glasgow; F. Cowie and J. White, NHS Greater Glasgow and Clyde-Western Inﬁrmary,
Glasgow; S. Picton and I. Lewis, Leeds General Inﬁrmary, Leeds; M. Leahy, D Stark and PJ. Selby, St James University Hospital,
© 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Whelan et al
Leeds; D. Heney and E. Ross, Leicester Royal Inﬁrmary, Leicester; B. Pizer and H. McDowell, Royal Liverpool Children’s Hospital
NHS Trust, Alder Hey, Liverpool; A. Michalski, Great Ormond Street Hospital for Children, London; J. Whelan, University College
Hospital NHS Trust, London; J. Chisholm and K. Pritchard-Jones, Royal Marsden NHS Trust, London; I. Judson, Royal Marsden
Hospital, London; B. Brennan, Royal Manchester Children’s Hospital and The Christie NHS Foundation Trust, Manchester; J. Hale
and Q. Campbell-Hewson, Royal Victoria Inﬁrmary, Newcastle upon Tyne; M. Verrill, Newcastle Upon Tyne, Newcastle; D. Walker,
Queens Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham; M. Sokal, Nottingham University Hospital
NHS Trust, Nottingham; K. Wheeler, Oxford Radcliffe Hospitals, Oxford; V. Lee and M. Gerrard, Shefﬁeld Children’s Hospital,
Shefﬁeld; P. Woll, P. Lorigan and M. Robinson, Weston Park Hospital, Shefﬁeld; J. Kohler and R. Ramanujachar, Southampton
General Hospital, Southampton.
jco.org © 2018 by American Society of Clinical Oncology
High-Dose Chemotherapy for Ewing Sarcoma
